Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Heron Therapeutics reported revenue of $40.59 million for the quarter ended December 2025, reflecting a year-over-year decline of 0.5% and an EPS of -$0.02 compared to $0.02 a year ago, with the revenue aligning with Zacks Consensus Estimate of $0 million and an EPS surprise of +33.33% against a consensus estimate of -$0.03 [1] Financial Performance - The company’s net product sales for Acute Care from APONVIE reached $3.81 million, exceeding the two-analyst average estimate of $3.58 million, marking a year-over-year increase of +97.4% [4] - Oncology product sales from SUSTOL were reported at $1.33 million, below the two-analyst average estimate of $1.6 million, representing a year-over-year decline of -62.3% [4] - CINVANTI generated net product sales of $22.92 million, which was lower than the two-analyst average estimate of $24.15 million, indicating a year-over-year decrease of -14.7% [4] - ZYNRELEF's net product sales amounted to $12.53 million, surpassing the average estimate of $10.23 million from two analysts, with a year-over-year growth of +48.2% [4] Stock Performance - Over the past month, shares of Heron Therapeutics have declined by -18.8%, contrasting with the Zacks S&P 500 composite's increase of +0.6%, and the stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]